Sector Gamma AS Acquires 7,327 Shares of Ascendis Pharma A/S $ASND

Sector Gamma AS boosted its holdings in shares of Ascendis Pharma A/S (NASDAQ:ASND) by 43.1% in the 3rd quarter, Holdings Channel.com reports. The firm owned 24,327 shares of the biotechnology company’s stock after purchasing an additional 7,327 shares during the quarter. Sector Gamma AS’s holdings in Ascendis Pharma A/S were worth $4,836,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors also recently added to or reduced their stakes in ASND. LVW Advisors LLC acquired a new stake in shares of Ascendis Pharma A/S in the second quarter worth $202,000. Allspring Global Investments Holdings LLC boosted its holdings in Ascendis Pharma A/S by 5.6% in the 2nd quarter. Allspring Global Investments Holdings LLC now owns 200,257 shares of the biotechnology company’s stock valued at $34,444,000 after purchasing an additional 10,644 shares during the period. Allianz Asset Management GmbH grew its position in Ascendis Pharma A/S by 144.7% in the 2nd quarter. Allianz Asset Management GmbH now owns 9,300 shares of the biotechnology company’s stock worth $1,605,000 after purchasing an additional 5,500 shares during the last quarter. Chicago Partners Investment Group LLC grew its position in Ascendis Pharma A/S by 4.5% in the 2nd quarter. Chicago Partners Investment Group LLC now owns 3,732 shares of the biotechnology company’s stock worth $635,000 after purchasing an additional 161 shares during the last quarter. Finally, R Squared Ltd bought a new position in shares of Ascendis Pharma A/S during the 2nd quarter worth about $209,000.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Ascendis Pharma A/S in a research note on Wednesday. Cantor Fitzgerald reiterated an “overweight” rating on shares of Ascendis Pharma A/S in a research report on Wednesday, November 26th. Wells Fargo & Company boosted their price objective on Ascendis Pharma A/S from $322.00 to $330.00 and gave the company an “overweight” rating in a research report on Tuesday. JPMorgan Chase & Co. raised their target price on Ascendis Pharma A/S from $260.00 to $264.00 and gave the stock an “overweight” rating in a research report on Thursday, October 9th. Finally, Wall Street Zen downgraded shares of Ascendis Pharma A/S from a “buy” rating to a “hold” rating in a research note on Saturday, November 15th. Two investment analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Ascendis Pharma A/S currently has a consensus rating of “Buy” and an average price target of $264.44.

Ascendis Pharma A/S Price Performance

ASND stock opened at $235.39 on Friday. The business has a fifty day moving average price of $210.60 and a 200 day moving average price of $199.63. Ascendis Pharma A/S has a fifty-two week low of $118.03 and a fifty-two week high of $238.84. The stock has a market capitalization of $14.59 billion, a price-to-earnings ratio of -53.02, a P/E/G ratio of 1.24 and a beta of 0.46.

Ascendis Pharma A/S (NASDAQ:ASND) last announced its earnings results on Thursday, November 13th. The biotechnology company reported ($1.17) EPS for the quarter, missing the consensus estimate of ($0.41) by ($0.76). The firm had revenue of $250.71 million during the quarter, compared to the consensus estimate of $246.91 million. On average, equities analysts expect that Ascendis Pharma A/S will post -4.34 earnings per share for the current fiscal year.

Ascendis Pharma A/S Profile

Ascendis Pharma A/S is a Denmark‐based biopharmaceutical company focused on developing innovative therapies for rare endocrine diseases. Founded in 2015 and headquartered in Hellerup, the company leverages its proprietary TransCon drug delivery platform to create long‐acting prodrugs designed to improve safety, efficacy and patient convenience. Ascendis Pharma maintains research and development operations in Europe and the United States, with clinical studies spanning North America, Europe and Asia.

The company’s lead product, lonapegsomatropin (Skytrofa®), is a once‐weekly growth hormone therapy approved by the U.S.